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S_ry The acquisition of the mulidrug resistance phenotype in human tumours is associated with an
overexpression of the 170 kDa P-glycoprotein encoded by the multidrug resistance I (MDR1) gene, and also
with a 190 kDa membrane ATP-binding protein encoded by a multidrug resistance-associated protein (MRP)
gene. Human bladder cancer is a highly malignant neoplasm which is refractory to anti-cancer chemotherapy.
In order to understand the hanism underying multidrug resistance in bladder cancer, we established three
doxorubicin-resistant cel lines, T24/ADM-1, T24/ADM-2 and KK47/ADM, and one vincristine-resistant cell
line, T24/VCR, from human bladder cancer T24 and KK47 cells respectively. Both T24/ADM-1 and
T24/ADM-2 cells which had elevated MRP mRNA levels showed both a cross-resistance to etoposide and a
decreased intracellular accumulation of etoposide. T24/VCR cells which had elevated levels of MDR1 mRNA
and P-glycoprotein but not of MRP mRNA, showed cross-resistce to doxorubicin. On the other hand,
KK47/ADM cells, which had elevated levels of both MRP and MDR1 mRNA and a decreased level of
topoisomerase II mRNA, were found to be cross-resistant to etoposide, vincristine and a camptothecin
derivative, CT-1I 1. Our present study demonstrates a concomitant induction of increased levels of MRP
mRNA, decreased levels of topoisomerase II mRNA and decreased drug accumulation during development of
multidrug resistance in human bladder cancer cells. The enhanced expression of the MRP gene is herein
discussed in a possible correlation with the decreased expression of the topoisomerase II gene.
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The overexpression of membrane P-glycoprotein (P-gp) with
Mr of 170 kDa, encoded by the human multidrug resistance
1 (MDRl) gene, is often associated with the acquisition of
the multidrug resistance phenotype (Bradley et al., 1988;
Gottesman and Pastan, 1988). The reduced drug retention in
P-gp-overexpressing cells is due to an enhanced active efflux
of anti-cancer agents. The MDR1 gene is often expressed in
various tumours from cancer patients (Goldstein et al., 1989),
but the expression of the MDRI-encoded P-gp is not always
coupled with the acquisition of multidrug-resistant pheno-
types in human tumours. One other form of multidrug resis-
tance, in which altered topoisomerase II activity is involved
(Takano et al., 1992), has been referred to as atypical multi-
drug resistance (Beck et al., 1987). Another form of multi-
drug resistance is non-Pgp-mediated multidrug resistance.
This type of multidrug resistance has been reported in doxo-
rubicin-selected lung carcinoma cell lines (Mirski et al., 1987;
Scheper et al., 1993; Barrand et al., 1994) and a leukaemia
cell line (Marsh et al., 1987) among others. Expression of a
190 kDa vesicular glycoprotein (Krishnachary et al., 1993)
and a 110 kDa membrane glycoprotein (Scheper et al., 1993)
appears to be associated with the non-P-gp-mediated multi-
drug resistance in some of these cell lines. Cole et al. (1992)
have isolated a gene named multidrug resistance-associated
protein (MRP) from a doxorubicin-sekcted small-cell lung
carcinoma cell line (H69AR): H69AR cells have a MDR
phenotype, but do not overexpress P-gp (Mirski et al., 1987).
This MRP gene is amplified in H69AR cells as well as in
several other cell lines that overexpress this mRNA (Slovak
et al., 1993; Zaman et al., 1993). MDR1 and MRP are both
members of the ATP-binding cassette (ABC) superfamily
transport system described by Hyde et al. (1990), but have
very little sequence homology with each other outside the
nucleotide-binding domains (Cole et al., 1992).
Anti-cancer agents such as etoposide, cisplatin, vincristine,
vinblastine, doxorubicin and others have been employed in
the therapy of human bladder cancer, but their therapeutic
effects are not satisfactory (Harry et al., 1987; Stemnberg et
al., 1988). Resistance to anti-cancer agents in bladder cancer
cells in culture and bladder tumour in vivo is sometimes
associated with an enhanced expression of P-gp or MDR1
gene (Naito et al., 1992; Shinohara et al., 1993; Kimiya et al.,
1992). However, we have also isolated multidrug-resistant cell
lines from bladder cancer cells without overexpression of
P-gp. It is thus important to know whether other multidrug
resistance-related genes play a role in multidrug resistance in
human bladder cancer. In the present study, we examined
whether overexpression of MRP is associated with acquired
multidrug resistance in human bladder cancer cells. Several
multidrug-resistant cell lines selected from human bladder
T24 or KK47 cells were found to express increased level of
MRP mRNA and protein. They also expressed decreased
levels ofDNA topoisomerase II mRNA, which indicated that
resistance in these bladder cell lines results from multiple
mechanisms.
Materak and wthod
Bladder twnour cells and their MDR cell lines
Both KK47 (Taya et al., 1977) and T24 (Bubenik et al.,
1973) were established from transitional cell carcinoma of the
bladder and were used as parental cell lines from which
multidrug-resistant cells were developed. A doxorubicin-
resistant cell line (KK47/ADM) from KK47 cells was estab-
lished as described previously (Kimiya et al., 1992).
Doxorubicin-resistant T24 cell lines, T24/ADM-1 and T24/
ADM-2, were independently established by exposure of the
T24 cell line for 3 months to the IC50 of doxorubicin fol-
lowed by a further exposure for 3 months to a 10-fold higher
dose of doxorubicin. A vincristine-resistant cell line (T24/
VCR) was established according to the same procedure.
These drug-resistant cell lines, KK47/ADM, T24/VCR, T24/
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ADM-l and T24/ADM-2, were cloned in the presence of
their selecting agents. All cell lines were cultured in minimal
essential medium (MEM) supplemented with 10% fetal
bovine serum (FBS), lOunitsml-' penicillin and 60mgml-'
kanamycin as described previously (Abe et al., 1994; Kotoh
et al., 1994).
Doubling times of KK47 and KK47/ADM cells were
27.0 h and 30.0 h in the presence of 10% FBS at 37°C.
Doubling times of T24/ADM-1, T24/ADM-2 and T24/VCR
were 28.0-35.0h; the doubling time of the parental T24 cells
was 25.0 h. This finding indicated that the growth rate of
each resistant cell line did not differ greatly from that of each
parental counterpart.
Drugs and chemicals
Doxorubicin was a gift from Kyowa Pharmaceuticals,
Tokyo, Japan, vincristine was from Shionogi Phar-
maceuticals, Tokyo, Japan and etoposide and cis-diamined-
ichloroplatinum(II) (cisplatin) were from Nihon Kayaku,
Tokyo, Japan. (4S)-4, 11-Diethyl-4-hydroxy-9-[(4-piperidino-
piperidino) carbonyloxy] dione hydrochloride tribyarate
(CPT-11) was from Yakult, Tokyo, Japan. [3H]Etoposide
(388 Cimmol-') was obtained from Moravek Biochemicals
(Brea, CA, USA), and [3Hlvincristine (4.8 Cimmol') was
obtained from New England Nuclear.
Cell survival by colonyformation
Cell survival was determined by plating approximately 103
cells in 35 mm dishes in the absence of any drug (Matsuo et
al., 1990; Takano et al., 1991; Abe et al., 1994). Various
drugs were added 24 h later. After incubation for 7 days at
37°C, the number of colonies was counted after Giemsa
staining. All drugs were freshly prepared in physiological
saline or dimethylsulphoxide. The same amount of saline or
dimethylsulphoxide was added. The 50% inhibition of cell
growth (IC50) for each cell line was determined from dose-
response curves of human bladder cancer cell lines.
Drug accumulation
The cells (1-2 x I05 per 24-well plate) were plated and
incubated for 48 h at 37°C. After reaching subconfluence, the
plates were incubated on ice in water at 4°C for 15 min and
the cells were washed twice with ice-cold phosphate-buffered
saline (PBS). Medium was then replaced with 200fl of buffer
(serum-free MEM and 20 mM Hepes, pH 7.5) containing
[3Hjetoposide (1gM, 1 tCi ml-1) and [3H]vincristine (22iLM,
0.13 Ciml-'), and the cells were incubated at 37°C as des-
cribed previously (Matsuo et al., 1990; Takano et al., 1991;
Abe et al., 1994). The cells were then washed with ice-cold
PBS three times, 400 i1 of 0.25 N sodium hydroxide added,
and then they were kept at 37TC for at least 30 min. The cell
lysates were mixed thoroughly with 4 ml of Scintisol EX-H
(Wako Chemicals, Osaka, Japan) and the radioactivity was
determined.
Fluorescence microscopy
Human bladder cancer cells in an exponential growth state
were centrifuged and suspended in MEM-10% FBS at 1 x
I05ml-'. The cells were seeded on a glass slide and incubated
at 37°C for 24 h. The cells were then incubated with 1jig
ml-I or greater concentrations of doxorubicin for 40 min at
37TC, followed by washing with ice-cold PBS twice, and
mounted in 50% glycerol in PBS. Fluorescence of doxo-
rubicin in the cells was examined by Nikon fluorescence
microscopy with a Bio-Rad laser scanning confocal imaging
system (MRC-600) (Abe et al., 1994).
Northernblot analysis and Southern blot analysis
A human MRP complementary DNA (cDNA) probe (1 kb
EcoRIfragment) (Cole et al., 1992) was used. Human MDRI
cDNA was from MM Gottesman (NCI, NIH, Bethesda,
MD, USA), human topoisomerase I cDNA probe from
OKoiwai and T Andoh (Aichi Cancer Center, Nagoya,
Japan) and human topoisomerase II cDNA probe (pBS-
hTOP2) from JC Wang (Harvard University, USA). A
Northern blot analysis was performed as described previously
(Abe et al., 1994; Kotoh et al., 1994). Human bladder cancer
cells were incubated in MEM containing 10% FBS, and the
harvested cells were suspended in 4 M guanidinum isothio-
cyanate, 25 mM sodium citrate (pH 7.0), 0.5% sarcosyl and
0.1 M P-mercaptoethanol. Sodium acetate (2 M) (pH 4.0),
water-saturated phenol and chloroform were added succes-
sively to samples. After mixing vigorously, the samples were
left on ice for 20 min and then were centrifuged at 10 000 g
for 20 min. The aqueous phase was removed, mixed with
isopropanol and kept at - 20°C for 60 min. The samples
were then centrifuged at 10 000 g for 20min and the RNA
pellet was washed with 75% ethanol and dissolved in sterile,
RNAse-free water. The RNA was fractionated through a 1%
agarose gel containing 2.2 M formaldehyde and transferred
onto a Hybond N+ filter (Amersham, Bucks, UK). Genomic
DNA was isolated from human bladder cancer cells and
Southern blotting was carried out according to the standard
protocols (Kohno et al., 1994). DNA was digested to com-
pletion with EcoRI. Ten micrograms of DNA was loaded in
each lane onto 0.8% agarose gel, and the DNA then trans-
ferred onto a Hybond N+ filter. The RNA and DNA blots
were hybridised with 32P-labelled cDNA probes in Hybrisol
for 24 h at 40°C, and then washed at room temperature in
2 x SSC and 0.1% SDS, followed by further washing in
0.2 x SSC and 0.1% SDS. The mRNA and DNA levels were
quantified by a densitometric analysis with a Fujix BAS 2000
bioimaging analyser (Fuji Photo Film, Tokyo, Japan).
Western blot anal sis
Western blot analysis was performed as described previously
(Ono et al., 1992; Kotoh et al., 1994). Vesicles were prepared
from drug-sensitive and drug-resistant cell lines by nitrogen
cavitation as described previously (Kiue et al., 1990). The
cells were grown to confluence in 10cm dishes. Cell mono-
layers (I09-10'0 cells) were washed once and scraped into
PBS. The cells were washed by centrifugation (4000g,
10 min) in PBS and then in vesicle buffer (0.01 M) Tris-HCI,
pH 7.5, 0.25 M sucrose, 0.2 mM calcium chloride). The cells
were then resuspended in vesicle buffer and equilibrated at
4°C under nitrogen pressure at 4000 p.s.i. for 15 min. Under
these conditions, more than 95% of the cells were lysed.
EDTA was added to the cell homogenate to a final concen-
tration of 1 mM. The homogenate was then diluted 1:4 with
0.01 M Tris-HCI pH 7.5-0.025 M sucrose and centrifuged at
1000g for 10min. To remove nuclei and unlysed cells. The
supernatant was layered onto a 35% sucrose cushion (0.01 M
Tris-HCI, pH 7.5, 35% sucrose, 1 mM EDTA) and centri-
fuged for 30 min at 16000g. The interface was collected and
diluted 1:1 in 0.01 M Tris-HCI, pH 7.5, 0.25 M sucrose, and
then was centrifuged for 45 min at 100 000g. The vesicle
pellet was resuspended in 0.01 M Tris-HCI pH 7.5-0.25 M
sucrose using a 25 gauge needle and the vesicle supsensions
were stored at - 80°C. Twenty micrograms of vesicle protein
was mixed with 4 x sample buffer (250 mM Tris-HCI pH 6.8,
containing 20% P-mercaptoethanol and 9% SDS), and then
subjected to SDS-PAGE in 7.5% gel. Proteins were then
electrophoretically transferred to a nitrocellulose filter. The
filters were blocked with 5% skimmed milk in Tris-buffered
saline (TBS) containing 0.1% Tween-20. All antibodies were
diluted with 1% skimmed milk in TBS containing 0.1%
Tween-20. For the detection of P-gp, MC64 was used. The
filter was incubated with 30jig ml-' anti-P-gp antibody for
1 h at room temperature. The second antibody, 1:100 diluted
anti-mouse IgG, was added and the filter was incubated for
45 mmn at room temperature. For the detection of MRP,
MAb QCRL1 (hybridoma supernatant) was used. The filters
were washed twice with 1% sk-immed milk in TBS containing
0.1% Tween-20 and once with TBS containing 0.1% Tween-Itdr -g remn bldder cancrcs
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20. Antibody binding was detected by enhanced
chemoluminescence (ECL) Western blotting method using
ECL Western blotting detection reagents (Amersham, UK)
by fluorography on Hyperpaper-ECL western (Amersham,
UK) for 1 min at room temperature as described previously
(Ono et al., 1992).
Results
Drug resistance to multiple anti-cancer agents in bladder
cancer cell lines
We compared the drugs sensitivities to doxorubicin,
etoposide, vincristine, cisplatin and CPT-11 of the drug-
resistant bladder cancer cell lines, KK47/ADM, T24/ADM-1,
T24/ADM-2 and T24/VCR, with those of their parental
counterparts. The dose-response curves of the six cell lines
to these anti-cancer agents were determined by colony for-
mation assay, and from these survival curves the doses
required to inhibit cell growth by 50% (IC50 were calculated
for each cell line. The relative drug resistances of KK47/
ADM, T24/ADM-1, T24/ADM-2 and T24/VCR cells were
determined by comparison with the IC50 of each parental
counterpart (Table I). As shown in Table I, KK47/ADM
cells were an 18.7-fold resistant to doxorubicin and 3.5- to
4.6-fold resistant to etoposide, vincristine and CPT-l1 com-
pared with KK47 cells. In contrast, T24/ADM-1 and T24/
ADM-2 showed 4.8- to 10.5-fold higher resistance to doxo-
rubicin and etoposide than T24, but only showed 1.2- to
1.9-fold higher resistance to vincrisine. T24/VCR cells
showed 6.8-fold and 15.1-fold higher resistance to doxo-
rubicin and vincristine, respectively, but only 1.8- to 3.1-fold
higher resistance to etoposide and CPT-l 1. The KK47/ADM,
T24/ADM-1 and T24/ADM-2 cell lines were not cross-resis-
tant to cisplatin, while T24/VCR showed 2-fold higher resis-
tance to cisplatin than T24 (Table I). Thus the four cell lines,
KK47/ADM, T24/ADM-1, T24/ADM-2 and T24/VCR, all
had acquired a multidrug resistance phenotype, but each cell
line appeared to show a unique cross-resistance pattern.
Cellular accumulation ofvincristine, etoposide and doxorubicin
The cellular accumulation of vincristine, etoposide and doxo-
rubicin is often reduced in multidrug-resistant cell lines
(Kohno et al., 1988; Matsuo et al., 1990). A reduced accumu-
lation of these agents may be responsible for the relatively
higher drug resistance in KK47/ADM, T24/ADM or T24/
VCR cells. The accumulation of [3Hjetoposide in these cell
lines reached steady-state levels within 20-40min at 37C
(data not shown). Cellular etoposide accumulation in KK47/
ADM and T24/ADM-1 or T24/ADM-2 cells was half or less
of that in each parental cell line (Figure 1). Etoposide
accumulation in T24/VCR cells was only slightly reduced, if
at all, in comparison with that in the T24 cells. The cellular
accumulation of [3H]vincristine in these cell lines reached a
plateau within 150min at 37TC (data not shown), and accu-
mulation of vincristine was measured at 20, 40, 60 and
120min (Figure 2). The cellular vincristine accumulation in
KK47/ADM was 30% or less than that in KK47. In T24/
ADM-1 and T24/ADM-2 cells, vincristine accumulation was
only slightly reduced if at all in companson with T24 cells.
By contrast, vincristine accumulation in T24/VCR cells was
greatly reduced in comparison with the parental T24 cells.
Doxorubicin accumulation in T24, T24/ADM-2 and T24/
VCR cells was compared using fluorescence microscopy. As
seen in Figure 3a, doxorubicin accumulated in the nuclei of
T24 cells when incubated for 40 min with the drug. This was
followed by a gradual decrease in intranuclear doxorubicin
concentration during further incubation for 120 min in the
absence of the drug. T24, T24/ADM-2 and T24/VCR cells
were first incubated with doxorubicin at 1 jLg ml-', 2jig ml-'
and 4 Lgml-', respectively, for 40 min. The level of doxo-
rubicin accumulation in the nuclei of T24/ADM-2 and T24/
VCR cells was similar to that of T24 cells when incubated
with drug for 40 min at 37C (Figure 3). However, doxo-
rubicin in nuclei was almost completely removed from T24/
ADM-2 and T24/VCR cells after further incubation for
120min in the absence of drug (Figure 3d and f), while
doxorubicin still remained in nuclei of the parental T24 cells
(Figure 3b).
The expression ofDNA topoisomerase I and II, MDR] and
MRP genes
Northern blot analysis was performed to determine if the
expression of drug resistance relevant genes such as MRP,
MDR1 and DNA topoisomerase I and II was altered in these
drug-resistant bladder cancer cell lines. The expression of
topoisomerase I was similar in all these bladder cell lines
(Figure 4a). In comparison with parental KK47 and T24
cells, the cellular levels of topoisomerase H mRNA expres-
sion were much lower in doxorubicin-resistant KK47/ADM,
T24/ADM-1 and T24/ADM-2 cells. The expression of the
MDR1 gene was found to be much higher in KK47/ADM
P.*I P..4l/ IZ IZ / IZ4/ I 4/
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Fugwe 1 Etoposide accumulation in the bladder cancer cell lines.
Human bladder cells were seeded and then incubated with I jLM
[3Hjetoposide for 20, 40 or 60min. The cell-associated radioac-
tivity was determined, and radioactivity per mg of protein was
calculated for each cell line. Each value represents the average of
triplicate dishes. Cellular accumulation of both drugs in these cell
lines is normaised by comparison with accumulation in parental
cells. Bars = s.d.
Table I Comparison of drug resistance to anti-cancer agents in KK47/ADM, T24/ADM-1, T24/ADM-2 and
T24/VCR cells
KK47 Relative resistancea T24 Relative resistance'
Anticancer drugs IC50 (nM) KK471ADM IC50 (nM) T24/ADM-1 T24/ADM-2 124/ VCR
Doxorubicin 14.7 2.1 18.7 16.8 ± 1.6 4.8 9.3 6.8
Etoposide 80.3 ± 5.4 3.5 47.6 ± 9.9 5.1 10.5 1.8
Vincristine 1.8 0.1 4.6 3.3 ± 1.2 1.2 1.9 15.1
Cisplatin 213.3 ± 52.3 0.6 200.0 ± 30.0 0.8 1.1 2.2
CPT-l1 433.8 91.2 3.5 378.5± 123.8 0.5 0.9 3.1
'Relative resistance was obtained by dividing the IC_% of resistant ceUl lines by the IC5n of parental ceUl lines. The
values represent the average of triplicate trials.
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Fugwe 2 Vincristine accumulation in the bladder cancer cell
lines. Human bladder cells were seeded and then incubated with
22tm [3H]vincristine for 20, 40, 60 or 120min. Cell-associated
radioactivity was determined, and radioactivity per mg of protein
was alculated for each cell line. Each value represents the
average of triplicate dishes. Cellular accumulation of both drugs
in these cell lines is normalised by comparison with accumulation
in parental cells. Bars = s.d.
Fige 3 The analysis ofdoxorubicin accumulation in T24, T24/
ADM-2 and T24/VCR cells using fluorescence microscopy. These
cells were incubated for 40min with doxorubicin (l.0iLgmn4-),
foIlowed by incubation in drug-free medium for 120 min. (a), (c)
and (e) show the fluorescence ofT24, T24/ADM-2 and T24/VCR
cells during the initial 40 min incubation. (b), (d) and (f) show the
fluorescence of T24, T24/ADM-2 and T24/VCR after further
incubation in drug-free medium for 120 min. We repeated two
independent assays, and obtained almost the same data as in this
analysis.
and T24/VCR cells than in their parental cell lines (Figure
4b, Table II). The cellular MDR1 mRNA level in KK47/
ADM cels was similar to that of a multidrug-resistant ceUl
line, VJ-300, which overexpresses P-gp, derived from human
epidermoid cancer KB ceUls (Kohno et al., 1988) but the
cellular MDR1 mRNA level in T24/VCR cells was lower
than in either KK47/ADM or KB/VJ300 ceUls. Consistent
with a previous report (Cole et al., 1992; Grant et al., 1994),
the MRP-specific probe hybridised to 6.5 kb RNA species
(Figure 4b). In comparison with drug-sensitive T24 cells, the
MRP mRNA levels increased 4- and 8-fold in T24/ADM-1
and T24/ADM-2 cells respectively, but overexpression of
Topo I
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FMgwe 4 Northern blot analysis for DNA topoisoomerase I and
II mRNA (a) and MDRI and MAP mRNA (b) in human
bladder cell lines. Twenty micrograms of RNA from each bladder
cancer cell line was loaded in each lane.
MRP mRNA in T24/VCR cells was not detected. MRP
mRNA levels were found to be 3-fold higher in KK47/ADM
cells than in KK47 cells. T24/VCR cells specifically overex-
pressed MDRl mRNA, while T24/ADM-l and T24/ADM-2
cells specifically overexpressed only the MRP mRNA levels.
KK47/ADM cells, however, had increased levels of both
MDRl and MRP mRNA. Two independent Northern blot
analyses demonstrated consistent results, as seen in Figure 4a
and b.
The enhanced expression of MRP mRNA in doxorubicin-
resistant small-ell lung cancer cell lines which were selected
in vitro is due to an amplification of the MRP gene (Cole et
al., 1992; Zaman et al., 1993). To determine whether the
elevated levels of MRP mRNA in KK47/ADM, T24/ADM-l
and T24/ADM-2 cells were due to an amplification of this
gene, Southern blot analysis of EcoRI-digested genomic
DNA from these cells was performed. As shown in Figure 5
and Table II, an approximately 17-fold amplification of the
MDR1 gene was observed in KK47/ADM cells compared
with KK47 cells, but no amplification of the MDR1 gene was
apparent in the T24/ADM-1, T24/ADM-2 and T24/VCR
cells. We could observe 2- and 4-fold amplification of the
MRP gene in T24/ADM-1 and T24/ADM-2, respectively,
whereas no amplification was observed in KK47/ADM cells
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Tabe k Sunummary of expression and amplification of drug resistance related
genes in KK47 and T24 cells and their resistant cell lnes
mRNA leve' DNA leveP
Cell line Topo I Topo n MDR lb MRP MDR 1 MRP
KK47 1.0 1.00 - 1.0 1.0 1.0
KK47/ADM 1.0 0.70 + 3.0 17.0 1.0
T24 1.0 1.00 - 1.0 1.0 1.0
T24/ADM-1 1.0 0.40 - 4.0 1.0 2.0
T24/ADM-2 1.0 0.25 - 8.0 1.0 4.0
T24/VCR 1.0 0.65 + 1.0 1.0 1.0
'Relative levels of mRNA and DNA of resistant cell lines are presented
normalised to the levels of their parental counterparts (see Figures 4 and 5).
bNorthern blot analysis (Figure 4b) demonstrated the absence (-) and presence
(+) of detectable MDRI mRNA molcules.
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Fugwe 5 Southern blot analysis of the MRP and MDR1 gene.
Genomic DNA was digested with EcoRI and hybridised with
MRP and MDRI probe. Molcular weight markers as indicated
by the arrows are in kilobasepairs.
(Figure 5). In T24/VCR cells, the MDR1 mRNA level was
appreciably increased, but no apparent amplification of the
MDR1 gene was observed (Figure 5, Table II).
KK47/ADM cells appeared to overexpress both MRP and
MDR1 mRNA. Western blot analysis was performed to
confirm whether both the 190 kDa MRP gene product and
the 170 k.Da P-gp in KK47/ADM cells also increased (Figure
6). Although the parental KK47 cells expressed multidrug
resistance-associated protein, KK47/ADM had about 3-fold
more MRP gene product than KK47 cells. Furthermore,
P-gp was also overexpressed in KK47/ADM cells, but since it
was not detectable in parental KK47 cells the relative in-
crease in P-gp expression could not be calculated (Figure 6).
P-gp-mediated drug-resistant cells exhibit elevated levels of
drug resistance to vinca alkaloids (vincristine) and anthracyl-
cines (daunomycin, doxorubicin), colchicine and actinomycin
D, as well as resistance to topoisomerase II-targeting agents
such as etoposide and teniposide (Bradley et al., 1988;
Kohno et al., 1989). On the other hand, non-P-gp-mediated
multidrug-resistant cell lines are often selected by exposure to
doxorubicin or etoposide, and some of these non-P-gp-medi-
ated resistant cell lines show increased MRP gene expression
(Cole et al., 1992; Krishnamachary et al., 1993; Slovak et al.,
1993; Zaman et al., 1993; Schenider et al., 1994). We have
established several doxorubicin-resistant sublines of human
bladder cancer KK47 and T24 cells in vitro by continuous
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Fugue 6 Wester blot analysis for MRP (a) and P-gp protein
(b). The membrane vesicles were prepared as described in
Materials and methods. Twenty micrograms of the membrane
vesicles was loaded in each lane. Moecular weight markers as
indicated by the arrows are in kilodaltons.
exposure to doxorubicin. KK47/ADM cells overexpressed
both MDRl and MRP genes when assayed by both Northern
blot and Western blot analyses: KK47/ADM cells were cross-
resistant (about 4-fold) to etoposide, vincristie and CFPT-l 1.
In contrast, both T24/ADM-1 and T24/ADM-2 cells overex-
pressed only the MRP gene. They were cross-resistant to
etoposide, but displayed only low levels of vincristine resis-
tance (less than 2-fold). A typical P-gp-mediated drug-
resistant T24/VCR cell line which overexpressed the MDR1
gene was cross-resistant to doxorubicin or CPT-l1, but was
only weakly resistant to etoposide or cisplatin. The acquisi-
tion of vincristine resistance in KK47/ADM cells might be
specifically correlated with P-gp overexpression rather than
with MRP expression, as seen in T24/VCR cells. By contrast,
drug resistance to etoposide in KK47/ADM and T24/ADM-1
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or T24 ADM-2 cells might be more closely related to MRP
overexpression. The cross-resistance to vincristine at low
levels (1.2- to 1.9-fold higher) might be also correlated with
the MRP gene in T24/ADM-1 and T24/ADM-2 cells which
overproduced only multidrug resistance-associated protein.
Grant et al. (1994) have demonstrated that the transfectants
of a full-length MRP cDNA expression vector display in-
creased resistance to doxorubicin, vincristine and etoposide
and increased expression of the 190 kDa MRP. Furthermore,
Kruh et al. (1994) have reported the application of a novel
approach involving expression complementary DNA library
transfer to the identification of drug resistance genes. Using
this approach, they establish that MRP is capable ofconferr-
ing a multidrug-resistant phenotype. Although the precise
function of this new ABC family protein, MRP, is not yet
known (Cole et al.. 1992; Grant et al., 1994), MRP might
play some role in intranuclear accumulation of doxorubicin
or of etoposide.
Cancer cell lines resistant to DNA topoisomerase I or II
targeting agents such as etoposide or CPT-1 1 often have
decreased topoisomerase I or II levels (Takano et al., 1992).
Furthermore, in non-P-gp-mediated multidrug-resistant cell
lines from various human tumours, a decreased expression of
the topoisomerase II gene has been observed with a con-
comitant enhancement of MRP gene expression (Cole et al.,
1992; Slovak et al., 1993; Zaman et al., 1993; Schneider et al.,
1994). MRP gene amplification and decreased topoisomerase
II gene expression are also concomitantly observed in non-P-
gp-mediated multidrug-resistant cell lines selected in human
prostatic cancer cells (M Nakagawa, Y Tasaki, H Tanimura,
K Kohno and M Kuwano, unpublished data). Consistent
with these findings, our non-P-gp-mediated multidrug-
resistant bladder cancer cell lines, KK47/ADM, T24/ADM-1
and T24/ADM-2. also had a higher expression of the MRP
gene and reduced expression of the topoisomerase II gene. In
most non-P-gp-mediated multidrug-resistant cell lines
associated with MRP gene overexpression, decreased DNA
topoisomerase II gene expression might be a prerequisite for
the enhancement of MRP gene expression. However, MRP
transfectants have unchanged levels of topoisomerase IIa and
topoisomerase IIli mRNA (Grant et al., 1994).
The enhanced expression of MRP mRNA in most resistant
cell lines which are selected in vitro is often due to
amplification of the MRP gene (Cole et al., 1992; Slovak et
al.. 1993; Zaman et al., 1993). On the other hand, Abe et al.
(1994) recently reported that expression of the MRP gene is
enhanced in some human glioma cells which show spon-
taneous multidrug resistance to vincristine, doxorubicin and
etoposide, and also that the higher MRP mRNA levels are
due not to gene amplification, but to transcriptional or post-
transcriptional events. Consistent with these glioma cell lines,
the increased MRP mRNA levels in KK47/ADM bladder
cells appear also to be due to transcriptional or post-
transcriptional activation, rather than to gene amplification.
By contrast, amplification of the MRP gene is probably the
main mechanism underlying increased MRP mRNA levels in
both T24/ADM-1 and T24/ADM-2 cells.
The accumulation of vincristine is often decreased in
cancer cell lines overexpressing P-gp or the MDRl gene, and
is consistent with the findings of our previous study
(Nakagawa et al., 1986; Shiraishi et al., 1987; Kohno et al.,
1988). A decreased accumulation of etoposide was observed
in bladder cancer cell lines overexpressing the MRP gene or
its product. Doxorubicin in the nuclei of T24/ADM-2 cells
was almost completely removed after incubation for 120 min
in the absence of drug, but this was not the case in the
parental T24 cells. For the most part, decreased accumula-
tion of etoposide or doxorubicin is observed in non-P-gp-
mediated drug-resistant cell lines which overexpress MRP
(Zaman et al., 1973; Krishnamachary et al., 1993; Scheneider
et al., 1994). Consistent with previous reports (Cole et al.,
1991; Scheneider et al., 1994), MRP might be somehow
involved in translocation of the anti-cancer drug from nuclei
into the cytoplasm rather than outward transport from cyto-
plasms. Marquardt and Center (1992) have demonstrated
that doxorubicin is localised at perinuclear regions when the
drug is removed from culture medium for non-P-gp-mediated
multidrug-resistant leukaemia cells overexpressing MRP.
Further study is required to determine how MRP modulates
the intracellular localisation of doxorubicin or etoposide.
In our present study, the enhanced expression of the MRP
gene, the reduced expression of the topoisomerase II and the
decreased drug accumulation were all concomitantly observ-
ed in non-P-gp-mediated drug-resistant human bladder cells.
Further study will determine whether MRP gene overexpres-
sion is obligatorily coupled to low topoisomerase II mRNA
levels, as well as to decreased drug accumulation in human
bladder cancer cells.
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